The estimated Net Worth of Springs Capital Management ... is at least $1.06 Milion dollars as of 3 November 2020. Springs Management owns over 250,000 units of Atea Pharmaceuticals stock worth over $1,063,181 and over the last 7 years Springs sold AVIR stock worth over $0.
Springs has made over 4 trades of the Atea Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently Springs bought 250,000 units of AVIR stock worth $6,000,000 on 3 November 2020.
The largest trade Springs's ever made was buying 600,000 units of Atea Pharmaceuticals stock on 28 July 2020 worth over $9,600,000. On average, Springs trades about 337,500 units every 237 days since 2018. As of 3 November 2020 Springs still owns at least 289,695 units of Atea Pharmaceuticals stock.
You can see the complete history of Springs Management stock trades at the bottom of the page.
Over the last 4 years, insiders at Atea Pharmaceuticals have traded over $279,832 worth of Atea Pharmaceuticals stock and bought 553,666 units worth $13,102,824 . The most active insiders traders include Andrew A. F. Hack, Franklin M Berger oraz Springs Capital Management .... On average, Atea Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $229,012. The most recent stock trade was executed by Bruce Polsky on 20 June 2024, trading 17,544 units of AVIR stock currently worth $61,229.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals executives and other stock owners filed with the SEC include: